Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Analogue obtained by disulfide bond cyclization of opium and neuropeptide FF receptor multi-target molecule BN-9 as well as preparation method and application thereof

A BN-9, neuropeptide technology, applied in the field of biochemistry, can solve the problems of low effective analgesic dose, maternal intolerant, long analgesic effect time, etc.

Active Publication Date: 2018-12-11
LANZHOU UNIVERSITY
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

After a lot of experimental research, the inventors obtained the opioid / NPFF receptor multi-target molecule BN-9 by introducing an amino acid residue with a sulfhydryl structure in the side chain and modifying it through disulfide bond cyclization. The results show that this new type of BN-9 disulfide bond cyclization analogue has a longer analgesic effect time, a lower effective analgesic dose, overcomes the defects of the parent molecule such as poor blood-brain barrier permeability, and Maintains the advantages of maternal intolerance, low addiction, low constipation, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Analogue obtained by disulfide bond cyclization of opium and neuropeptide FF receptor multi-target molecule BN-9 as well as preparation method and application thereof
  • Analogue obtained by disulfide bond cyclization of opium and neuropeptide FF receptor multi-target molecule BN-9 as well as preparation method and application thereof
  • Analogue obtained by disulfide bond cyclization of opium and neuropeptide FF receptor multi-target molecule BN-9 as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] The synthetic method of embodiment 1 compound 1-8:

[0082] Experimental reagents: the resin is Rink-Amide-MBHA-Resin (substitution value S is 0.43mmol / g; Tianjin Nankai Hecheng Company), O-benzotriazole-N, N, N', N'-tetramethyl Urea-hexafluorophosphate (HBTU) (Shanghai Gil Biochemical Co., Ltd.), N-hydroxybenzotriazole (HOBt) (Shanghai Gil Biochemical Co., Ltd.), N, N-diisopropylethylamine (DIEA) ( Beijing Bailingwei), 1,8-diazabicycloundec-7-ene (DBU; Bailingwei). Ninhydrin is a product of Shanghai Reagent No.3 Factory. Dichloromethane (DCM), N,N-dimethylformamide (DMF), hexahydropyridine (piperidine), methanol (MeOH) and pyridine were all purchased from Tianjin Second Reagent Factory, trifluoroacetic acid (TFA), Phenol and pyridine are both products of Tianjin Reagent No. 1 Factory; the above organic reagents were redistilled before use.

[0083] Experimental equipment: solid-phase peptide synthesizer (designed by our laboratory), rotary evaporator (RE-5298A, Shan...

Embodiment 2

[0169] The in vitro functional activity assay of embodiment 2 analogs to opioid and NPFF receptors:

[0170] In stable expression of Mu-, Delta-, Kappa-opioid and NPFF 1 and NPFF 2 In HEK293 cells with receptors, their effects on these five receptors were detected by examining the regulation of the multi-target cyclized polypeptide of the opioid and NPFF receptors on Forskolin-induced intracellular cyclic adenosine monophosphate (cAMP) accumulation. agonistic activity. The specific method is: stably expressing Mu-, Delta-, Kappa-opioid and NPFF 1 and NPFF 2 Recipient HEK293 cells were seeded in 24-well plates at 120,000 cells per well, and cultured in an incubator for more than 20 hours. At the beginning of the experiment, the cell culture medium was replaced with preheated serum-free medium containing 1 mM IBMX, and incubated at 37°C for 10 min. Then, 10 μl of the drug to be tested and 10 μM forskolin (final concentration) were added to each well, and incubated at 37° ...

Embodiment 3

[0177] The in vitro enzymolysis stability measurement of embodiment 3 analogs:

[0178] Enzymatic Stability Test, an in vitro test to identify the stability of drugs in brain homogenate or plasma. Following incubation of compounds with brain homogenates or plasma, samples were analyzed for concentration by reverse phase HPLC. The half-life of the compound is then calculated. The specific method of enzymatic stability test is as follows:

[0179] 30±5g adult male mice were sacrificed by cervical dislocation, and the brain was removed (cerebellum and pons were removed), washed several times with ice-cold 1mM Tris-HCl buffer solution (pH=7.4) to remove residual blood on the brain, and blotted dry with filter paper , weighing. Add 50 times the volume of ice-cold 1 mM Tris-HCl (pH=7.4) (w / v=2%) buffer, place on ice for homogenization. The homogenate was placed in an ice bath for 30 minutes to facilitate cell lysis. Then add 0.5ml of 50mM ice-cold Tris-HCl for every 1ml of ho...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an analogue obtained by disulfide bond cyclization of opium and neuropeptide FF receptor multi-target molecule BN-9. By adopting BN-9 as a chemical template to introduce a sidechain thiol-containing amino acid residue for multi-site substitution modifications, and through cyclization modification, a series of disulfide bond cyclization analogues are obtained. The inventionalso discloses a preparation method and application of the analogues obtained by disulfide bond cyclization of opium and neuropeptide FF receptor multi-targeted molecule BN-9. These analogs simultaneously activate opium and the neuropeptide FF receptor, mediate high-efficiency, and have analgesic effects free from tolerance. Half-life period, blood-brain barrier penetration, and in vivo analgesiatime of the cyclized analogues of BN-9 are greatly improved relative to the matrix. Thus, the disulfide cyclized analogues of the BN-9 can be used for preparing analgesic drugs.

Description

technical field [0001] The invention belongs to the technical field of biochemistry, and specifically relates to a class of analogs of opioid and neuropeptide FF receptor multi-target molecule BN-9, a preparation method and application thereof. Background technique [0002] Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage that is subjective. Under normal physiological conditions, pain serves as a protective mechanism to prevent the body from being injured, but under pathological conditions, pain is intertwined with autonomic nervous activity, motor reflexes, psychological and emotional responses, causing suffering to patients, especially chronic pain It is a clinical problem that has not been fully resolved. The current clinical first-line opioid analgesics are often accompanied by opioid side effects, such as constipation, vomiting, respiratory depression, sedation, and drug dependence, while treating moderate or seve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06C07K1/04C07K1/06A61K38/08A61P29/00
CPCA61K38/00A61P29/00C07K7/06
Inventor 方泉张梦娜王锐许彪石学睿
Owner LANZHOU UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com